Abstract
Combined Efficacy of Diosmin and Ulinastatin on Renal Injury Markers and Ultrasound Indicators in Delayed Renal Function Recovery
Department of Urology, Beijing Water Resources Hospital, Haidian, Beijing 100036, 1Department of Urology, The Eighth Medical Center of People's Liberation Army General Hospital, Beijing 100091, China
Correspondence Address:
Ming Yuan, Department of Urology, Beijing Water Resources Hospital, Haidian, Beijing 100036, China, E-mail: gaohong@cfau.edu.cn
Renal transplantation, as an effective treatment for end-stage renal disease, has many clinical complications, among which delayed graft function recovery, as one of the common postoperative complications, is also a major risk factor affecting the short-term and long-term efficacy of renal transplantation. Therefore, reasonable use of delayed graft function after renal transplantation to promote renal function recovery is of great significance for the prognosis of these patients. Based on this, 62 patients who underwent renal transplantation and developed delayed graft function in our hospital from June 2017 to December 2019 were selected as the research objects. According to the random color method, they were divided into three groups; diosmin group (n=20), ulinastatin group (n=21) and combination group (n=21). To observe the effects of different medication regimens on renal injury markers and renal ultrasound related indexes in patients with delayed graft function and to lay a theoretical foundation for guiding clinical medication and improving prognosis of delayed graft function recovery patients. After comparing the general data of the three groups, it was found that there was no significant difference (p>0.05), indicating that there was no difference in medication results due to personal factors. The levels of serum creatinine, cystatin and blood urea nitrogen in the ulinastatin group after treatment were significantly better than those before treatment. The levels of renal injury markers in the combined group were significantly better after treatment than before treatment. According to the ultrasound results, there was no significant difference in the renal ultrasound indexes between the diosmin and ulinastatin groups after treatment, while the renal ultrasound indexes of the combined group were better than those of the other two groups. It can be concluded from the results that diosmin combined with ulinastatin can significantly reduce renal injury in patients with delayed graft function and can effectively improve renal function in such patients, which has a positive effect on improving prognosis.
